The Supervisory Board of Medios AG has appointed Stefan Bauerreis as a member of the Executive Board and as the Company's new Chief Financial Officer, effective April 15, 2026. He succeeds Falk Neukirch, who will step down at his own request at the end of his regular term of office on April 30, 2026. With the appointment of Stefan Bauerreis, Medios gains an experienced finance expert with many years of international leadership experience in industry and at publicly traded companies. Among other roles, he served as Chief Financial Officer of the Stabilus Group and held various senior finance positions within the Schaeffler Group for more than two decades, including as CFO for the Europe region and CFO for Germany. Stefan Bauerreis possesses extensive expertise in Corporate Accounting, Controlling, Financing, and the transformation and management of international companies.
Dr. Yann Samson, Chairman of the Supervisory Board of Medios AG, stated that with Stefan Bauerreis, the company is gaining a proven financial expert with extensive experience in internationally positioned SDAX and MDAX companies. He noted that Bauerreis combines operational excellence with strategic foresight and has repeatedly demonstrated throughout his career that he can successfully lead companies through periods of transformation. The Supervisory Board is convinced that he will provide important momentum for the future development of Medios. Stefan Bauerreis expressed his enthusiasm for the new role, stating that he looks forward to helping shape the future of Medios AG as part of the Executive Board. As CFO, he will contribute to further expanding the success of the Medios Group and its position as a leading Specialty Pharma company, both nationally and internationally, in the best interest of shareholders and employees.
The leadership transition occurs as Medios prepares for several important events in the 2026 financial year, including the Metzler Small Cap Days in Frankfurt on April 15, the TP ICAP Midcap Conference in Paris on May 6, and the company's Annual General Meeting on June 10. The company will also release its quarterly statement as of March 31, 2026 on May 12, followed by the Half-Year Financial Report on August 12 and the Medios Capital Markets Day on September 28-29. Additional information about the company's operations and focus on individualized medicine is available at https://app.medios.group/en/individualizedmedicine.
The appointment signals Medios's commitment to strengthening its financial leadership as it continues to expand its position in the European specialty pharmaceutical market. As Germany's first listed specialty pharmaceutical company, with shares traded on the regulated market of the Frankfurt Stock Exchange and included in the SDAX selection index, Medios operates across multiple European countries including Germany, the Netherlands, Belgium and Spain. The company focuses on pioneering individualized medicine to make innovative therapies available through partnerships with pharmacies, specialist practices and pharmaceutical companies.
